Active Biotech AB (publ) (ACTI.ST)
SEK 0.11
(-7.32%)
SEK 0.11
(-7.32%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -46.48 Million SEK | 19.7% |
| 2022 | -57.88 Million SEK | -16.28% |
| 2021 | -49.78 Million SEK | -54.1% |
| 2020 | -32.3 Million SEK | -0.07% |
| 2019 | -32.28 Million SEK | -8.19% |
| 2018 | -29.84 Million SEK | 70.89% |
| 2017 | -102.52 Million SEK | -86.0% |
| 2016 | -55.12 Million SEK | 69.02% |
| 2015 | -177.92 Million SEK | 22.12% |
| 2014 | -228.46 Million SEK | -9.3% |
| 2013 | -209.02 Million SEK | -28.07% |
| 2012 | -163.21 Million SEK | -61.72% |
| 2011 | -100.92 Million SEK | 55.92% |
| 2010 | -228.96 Million SEK | -4.28% |
| 2009 | -219.57 Million SEK | -18.95% |
| 2008 | -184.6 Million SEK | 8.92% |
| 2007 | -202.68 Million SEK | -62.71% |
| 2006 | -124.57 Million SEK | 6.51% |
| 2005 | -133.24 Million SEK | -166.34% |
| 2004 | 200.85 Million SEK | -40.3% |
| 2003 | 336.43 Million SEK | -1.37% |
| 2002 | 341.11 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -10.7 Million SEK | 16.41% |
| 2024 Q3 | -8.1 Million SEK | 24.3% |
| 2024 Q2 | -10.7 Million SEK | 0.0% |
| 2023 FY | -46.48 Million SEK | 19.7% |
| 2023 Q2 | -11.3 Million SEK | 4.24% |
| 2023 Q3 | -10.6 Million SEK | 6.19% |
| 2023 Q1 | -11.8 Million SEK | 22.81% |
| 2023 Q4 | -12.8 Million SEK | -20.75% |
| 2022 Q3 | -13.4 Million SEK | 4.29% |
| 2022 Q1 | -16.1 Million SEK | 0.51% |
| 2022 Q4 | -15.28 Million SEK | -14.07% |
| 2022 Q2 | -14 Million SEK | 13.04% |
| 2022 FY | -57.88 Million SEK | -16.28% |
| 2021 Q2 | -12.6 Million SEK | -29.9% |
| 2021 Q3 | -11.3 Million SEK | 10.32% |
| 2021 FY | -49.78 Million SEK | -54.1% |
| 2021 Q4 | -16.18 Million SEK | -43.2% |
| 2021 Q1 | -9.7 Million SEK | -136.24% |
| 2020 Q1 | -9.7 Million SEK | 13.28% |
| 2020 Q2 | -10.1 Million SEK | -4.12% |
| 2020 Q4 | -4.1 Million SEK | 50.53% |
| 2020 FY | -32.3 Million SEK | -0.07% |
| 2020 Q3 | -8.3 Million SEK | 17.82% |
| 2019 FY | -32.28 Million SEK | -8.19% |
| 2019 Q4 | -11.18 Million SEK | -20.27% |
| 2019 Q2 | -5.4 Million SEK | 15.63% |
| 2019 Q1 | -6.4 Million SEK | 9.1% |
| 2019 Q3 | -9.3 Million SEK | -72.22% |
| 2018 FY | -29.84 Million SEK | 70.89% |
| 2018 Q4 | -7.04 Million SEK | -2.04% |
| 2018 Q1 | -8.5 Million SEK | 85.43% |
| 2018 Q3 | -6.9 Million SEK | 5.48% |
| 2018 Q2 | -7.3 Million SEK | 14.12% |
| 2017 Q3 | -6.5 Million SEK | 71.86% |
| 2017 Q1 | -14.6 Million SEK | -7.96% |
| 2017 Q4 | -58.32 Million SEK | -797.35% |
| 2017 Q2 | -23.1 Million SEK | -58.22% |
| 2017 FY | -102.52 Million SEK | -86.0% |
| 2016 Q1 | -16.1 Million SEK | 42.96% |
| 2016 Q4 | -13.52 Million SEK | -21.84% |
| 2016 Q3 | -11.1 Million SEK | 23.45% |
| 2016 Q2 | -14.5 Million SEK | 9.94% |
| 2016 FY | -55.12 Million SEK | 69.02% |
| 2015 Q1 | -57.4 Million SEK | -3.13% |
| 2015 FY | -177.92 Million SEK | 22.12% |
| 2015 Q4 | -28.22 Million SEK | -27.15% |
| 2015 Q3 | -22.2 Million SEK | 68.33% |
| 2015 Q2 | -70.1 Million SEK | -22.13% |
| 2014 Q3 | -55.7 Million SEK | 3.8% |
| 2014 Q4 | -55.66 Million SEK | 0.07% |
| 2014 FY | -228.46 Million SEK | -9.3% |
| 2014 Q1 | -59.2 Million SEK | 26.39% |
| 2014 Q2 | -57.9 Million SEK | 2.2% |
| 2013 Q4 | -80.42 Million SEK | -388.26% |
| 2013 FY | -209.02 Million SEK | -28.07% |
| 2013 Q1 | -77 Million SEK | -1500.0% |
| 2013 Q3 | 27.9 Million SEK | 135.09% |
| 2013 Q2 | -79.5 Million SEK | -3.25% |
| 2012 Q1 | -100.7 Million SEK | -6.34% |
| 2012 Q4 | 5.5 Million SEK | 111.41% |
| 2012 Q3 | -48.2 Million SEK | -142.21% |
| 2012 Q2 | -19.9 Million SEK | 80.24% |
| 2012 FY | -163.21 Million SEK | -61.72% |
| 2011 FY | -100.92 Million SEK | 55.92% |
| 2011 Q1 | -70.9 Million SEK | 10.55% |
| 2011 Q2 | 141.5 Million SEK | 299.58% |
| 2011 Q3 | -76.8 Million SEK | -154.28% |
| 2011 Q4 | -94.7 Million SEK | -23.31% |
| 2010 Q3 | -47.3 Million SEK | 7.8% |
| 2010 Q2 | -51.3 Million SEK | -0.79% |
| 2010 Q4 | -79.26 Million SEK | -67.58% |
| 2010 Q1 | -50.9 Million SEK | 7.41% |
| 2010 FY | -228.96 Million SEK | -4.28% |
| 2009 Q2 | -54.8 Million SEK | 13.97% |
| 2009 Q1 | -63.7 Million SEK | 0.0% |
| 2009 Q3 | -46.1 Million SEK | 15.88% |
| 2009 FY | -219.57 Million SEK | -18.95% |
| 2009 Q4 | -54.97 Million SEK | -19.25% |
| 2008 FY | -184.6 Million SEK | 8.92% |
| 2007 FY | -202.68 Million SEK | -62.71% |
| 2006 FY | -124.57 Million SEK | 6.51% |
| 2005 FY | -133.24 Million SEK | -166.34% |
| 2004 FY | 200.85 Million SEK | -40.3% |
| 2003 FY | 336.43 Million SEK | -1.37% |
| 2002 FY | 341.11 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 81.33% |
| Ziccum AB (publ) | -21.56 Million SEK | -115.603% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -183.422% |
| BioArctic AB (publ) | 252.64 Million SEK | 118.399% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -5401.065% |
| Mendus AB (publ) | -100.65 Million SEK | 53.816% |
| Genovis AB (publ.) | 54.22 Million SEK | 185.726% |
| Intervacc AB (publ) | -93.57 Million SEK | 50.326% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -199.665% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 358.115% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 16.12% |
| Aptahem AB (publ) | -10.1 Million SEK | -360.021% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 85.542% |
| Kancera AB (publ) | -65.04 Million SEK | 28.532% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 65.469% |
| Fluicell AB (publ) | -26.87 Million SEK | -72.938% |
| Saniona AB (publ) | -81.06 Million SEK | 42.658% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -275.75% |
| Biovica International AB (publ) | -126.07 Million SEK | 63.129% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -9.361% |
| AcouSort AB (publ) | -17.48 Million SEK | -165.82% |
| Xintela AB (publ) | -57.23 Million SEK | 18.788% |
| Abliva AB (publ) | -96.54 Million SEK | 51.854% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 85.688% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -1226.22% |
| OncoZenge AB (publ) | -15.9 Million SEK | -192.315% |
| Amniotics AB (publ) | -29.07 Million SEK | -59.887% |
| 2cureX AB (publ) | -36.36 Million SEK | -27.833% |
| CombiGene AB (publ) | -36.3 Million SEK | -28.037% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -217.514% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 87.907% |
| Camurus AB (publ) | 532.35 Million SEK | 108.732% |
| Corline Biomedical AB | -1.78 Million SEK | -2499.776% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 74.285% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -11.518% |
| I-Tech AB | 24.43 Million SEK | 290.235% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 94.105% |
| Cyxone AB (publ) | -21.66 Million SEK | -114.598% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 56.133% |
| Biosergen AB | -27.26 Million SEK | -70.49% |
| Cantargia AB (publ) | -290.01 Million SEK | 83.972% |
| NextCell Pharma AB | -43.17 Million SEK | -7.671% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 74.285% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -171.895% |
| Nanologica AB (publ) | -69.96 Million SEK | 33.559% |
| SynAct Pharma AB | -224.49 Million SEK | 79.294% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -5.225% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -94.053% |
| LIDDS AB (publ) | -40.67 Million SEK | -14.284% |
| Lipum AB (publ) | -37.25 Million SEK | -24.776% |
| BioInvent International AB (publ) | -369.94 Million SEK | 87.435% |
| Alzinova AB (publ) | -16.52 Million SEK | -181.346% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 81.659% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -627.079% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 59.605% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -130.816% |
| Simris Alg AB (publ) | -36.63 Million SEK | -26.884% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 68.285% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 85.026% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 58.09% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -301.902% |